WHO ICTRP trial
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
JPRN-jRCT2031210442 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2031210442 |
|---|---|
| Public title | Study of PF-07265807 in Participants With Metastatic Solid Tumors. |
| Scientific title | A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF 07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES |
| Primary sponsor | Kawai Norisuke |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 1 |
| Countries | United States;Japan |
| Conditions | Solid Tumor |
| Interventions | Drug: PF-07265807 Given QD 2 weeks on/1 week off Other Name: ARRY-067 Drug: PF-07265807 Given QD 2 weeks on/1 week off Other Name: ARRY-067 Drug: Sasanlimab Given SC 225 mg Q3W Other Name: PF-06801591; RN-888 Drug: PF-07265807 Given QD 2… |
| Registration date | Nov 22, 2021 |
| Target size | 155 |
| Secondary IDs | NCT04458259 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: